8The spiral-ganglion hypothesis
This is the idea the whole chapter has been building toward. A cochlear implant does not restore the cochlea; it bypasses it, injecting its signal directly into the spiral-ganglion neurons. It follows that what matters for the implant is not whether the ear is damaged, but where. A genetic lesion that lies upstream of the electrode — in the hair cells and supporting cells of the membranous labyrinth — is simply bypassed, and the implant works well. A lesion in the spiral ganglion itself sits at the electrode's own target and cannot be bypassed, so the implant struggles. That single principle — the spiral-ganglion hypothesis — turns a genotype into a prognosis.
TThe thesis in one sentence
Eppsteiner and colleagues framed it crisply: mutations in genes expressed in the membranous labyrinth do not compromise cochlear-implant performance, whereas mutations in genes expressed in the spiral-ganglion neurons may lead to poor performance. The deafness is the same on the audiogram; the implant result diverges because the site of the lesion differs relative to where the electrode does its work.[2012]
CWhy the electrode's position decides it
The logic is purely anatomical. Sound normally runs hair cells → spiral ganglion → auditory nerve → brain. A cochlear implant enters this chain at the spiral ganglion, stimulating those neurons directly and letting the patient's own healthy nerve carry the signal onward. So the decisive question for any deafness gene is whether its lesion sits upstream of that entry point (and is bypassed) or at it (and is not). Toggle the lesion site below to see it.
CThe evidence
The pattern across reported genotypes fits the hypothesis. The membranous-labyrinth genes — GJB2, SLC26A4, OTOF, the mitochondrial genes — are consistently associated with good implant performance (Module 9). The spiral-ganglion genes — TMPRSS3, the deafness-dystonia gene TIMM8A — are associated with variable or poor performance. The correspondence between predicted site and observed outcome is what gives the hypothesis its prognostic force.[2012]
CThe anatomical backstop
The hypothesis rests on a long-established anatomical fact: the implant depends on surviving spiral-ganglion neurons to stimulate, and where those neurons have degenerated, performance suffers. Human temporal-bone studies showed decades ago that spiral-ganglion survival varies with the cause of deafness — the structural counterpart of the genetic prediction. Genes that attack the ganglion are simply the molecular route to the same end the temporal-bone studies measured anatomically.[1989, 2012]
CWhat the hypothesis does not yet settle
It remains a hypothesis, and an honest account notes its edges. Genotype-phenotype data in implant recipients are still limited; for many genes the effect on performance is unknown. Spiral-ganglion degeneration follows a continuum rather than an all-or-none rule, which blurs predictions. And outcome is multifactorial — age at implantation, duration of deafness and rehabilitation all act alongside genotype. The spiral-ganglion hypothesis is a powerful organising principle and a research programme, not a deterministic verdict on any individual.
With the principle established, the next module makes it concrete — gene by gene, who implants well and who does not (Module 9).
What is the clearest way to explain the predicted difference?
State the spiral-ganglion hypothesis.
What is an important limitation of the hypothesis in practice?